Market revenue in 2022 | USD 150.6 million |
Market revenue in 2030 | USD 906.6 million |
Growth rate | 25.2% (CAGR from 2022 to 2030) |
Largest segment | Cell therapy |
Fastest growing segment | Gene Therapy |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Gene Therapy, Cell Therapy |
Key market players worldwide | Lonza Group Ltd, Bluebird bio Inc, Catalent Inc, Roche, Samsung BioLogics, Boehringer Ingelheim, Hitachi Ltd, Takara Bio Inc, Miltenyi Biotec, Thermo Fisher Scientific Inc, Novartis AG ADR, Merck KGaA, Wuxi AppTec Co Ltd |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy manufacturing market will help companies and investors design strategic landscapes.
Cell therapy was the largest segment with a revenue share of 63.61% in 2022. Horizon Databook has segmented the Russia cell and gene therapy manufacturing market based on gene therapy, cell therapy covering the revenue growth of each sub-segment from 2018 to 2030.
The Russian healthcare and pharmaceutical markets have huge potential for stem cell studies & clinical trials owing to large clinical trial participation, favorable currency exchange rates, and quick patient enrollment. Quick patient enrollment is important for early phase trials to facilitate faster project initiation.
Moreover, constant government support coupled with rapid advancements in the cell & gene therapy manufacturing field is contributing to regional growth. The federal law on biomedical cell products, which came into effect in 2017, was introduced in Russia permitting the use of living cells for therapy.
This law would further boost the development of biomedical research, and patients would receive effective treatment with the use of artificially grown cells. However, owing to the current invasion of Ukraine by Russia, several countries have imposed restrictions against Russia and most private companies have removed their services from the country.
Horizon Databook provides a detailed overview of country-level data and insights on the Russia cell and gene therapy manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into Russia cell and gene therapy manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account